Abrantes, AM

Almeida-Ferreira, C

Botelho, MF

Caramelo, F

Figueiredo, A

Laranjo, M

Marques, I

Neves, R

Silva-Teixeira, R

Tavares da Silva, E

Name not available

Selective ablating urologic cancers with cold atmospheric plasma

Repositório Institucional dos Hospitais da Universidade de Coimbra

sutr-chuc.pt nesu.pt/sutr.chuc@sutr_nesuF O L L O W  U S  O N : H O M E P A G E S :Selective ablating urologic cancers with cold atmospheric plasma Almeida-Ferreira, C.a,b; Tavares-da-Silva, E.b,c,f; Silva-Teixeira, R.b; Laranjo, M.b,c,d; Marques, I.b; Neves, R.b, Abrantes; A.M.b,c,d; Caramelo, F.c; Figueiredo, A.c,f; Botelho, M.F.b,c,da) Faculty of Sciences and Technology, University of Coimbra; b) Biophysics Institute, Faculty of Medicine, University of Coimbra; c) CIMAGO, Faculty of Medicine, University of Coimbra; d) CNC.IBILI, University of Coimbra; e) Faculty of Pharmacy, University of Coimbra; f) Urology and Renal Transplantation Department, CHUC• Prostate and bladder cancers are the first and fourth most common noncutaneous cancers in men in developed nations• Plasma is also called the fourth state of matter• Ionized gas composed of reactive species, electrical and excited particles• Cold plasmas recently came into the attention of medical society due to its non-inflammatory selective ablative effects in tumour cells• Their effects result from different interactions between plasma components with specific structural cell elements as well as cell functionalities• Their selectivity of action results from the lower antioxidant defenses of tumor cells and the cell cycle block at phase G2/M in rapidly multiplying cells• Plasma therapy is still a developing field, but it seems to be effective against a wide range of tumors – melanoma, glioblastoma, breast, colon, lung and cervix cancer• Little is known about its role in the treatment of urologic neoplasms• Goal: The aim of this work was to evaluate the cytotoxicity of cold atmospheric plasma (CAP) in prostate and urinary bladder cancer cell lines• CAP is effective on LNCaP and HT1376 cells – over 90% decrease in metabolic activity and protein content after only 60s of exposure• Regarding to PC3 prostate cancer cell line, there was a decrease in metabolic activity after 60 seconds similar to the other two tumor lines, but the protein content did not have the same reaction even with 120s of exposure• For the same exposure conditions, there was less change din metabolic activity or protein content of the normal fibroblast line• CAP may offer a selective anti-tumour therapy capable of providing ablation of tumours after short time courses, typically in the range of seconds-minutes, without damaging with adjacent normal tissues• Further studies are needed to determine the utility of CAP in the treatment of bladder and prostate cancerDISCUSSIONMATERIALS AND METHODSINTRODUCTION RESULTSREFERENCES• Silva-Teixeira, R. et al. Cold atmoshperic plasma as an approach to retinoblastoma. Eur. J. Cancer 61, S143 (2016).• Gay-Mimbrera, J. et al. Clinical and Biological Principles of Cold Atmospheric Plasma Application in Skin Cancer. Adv. Ther. 33, 894–909 (2016).• Hoffmann, C., Berganza, C. & Zhang, J. Cold Atmospheric Plasma: methods of production and application in dentistry and oncology. Med. Gas Res. 3, 21 (2013).• von Woedtke, T., Reuter, S., Masur, K. & Weltmann, K. D. Plasmas for medicine. Phys. Rep. 530, 291–320 (2013).• Ahn, H. J. et al. Atmospheric-pressure plasma jet induces apoptosis involving mitochondria via generation of free radicals. PLoS One 6, (2011).LNCaP                         PC3Prostate cancerHT1376Bladder cancerHFF-1Normal Fibroblasts15-120s 15-120s 15-120s 15-120s• Our group developed an electronic device capable of generating high output voltage that can ionize a significant fraction of air particles producing cold atmospheric plasma (CAP)• Cell lines - plated in a concentration of 50.000-100.000 cells/mL in 200pL of cell culture medium• Prostate adenocarcinoma - LNCaP and PC3• Urinary bladder carcinoma - HT1376• Phenotypically normal human fibroblasts cell line - HFF-1• The device was designed to expose cell cultures seeded in multiwell plates to short periods of CAP• Range from 15 to 120 seconds• Metabolic activity (MA) and protein content (P) were assessed with colorimetric assays MTT and SRB, respectivelyP C 3T im e  ( s )Metabolic activity (%)1530609012005 01 0 0*************L nC apT im e  ( s )Metabolic activity (%)1530609012005 01 0 0****** ********H T 1376T im e  ( s )Metabolic activity (%)1530609012005 01 0 0** ***********H FF 1T im e  ( s )Metabolic activity (%)1530609012005 01 0 0********Figure 1 - MTT assay results 24 h after plasma therapy application in different human celllines: prostate adenocarcinoma (PC3 and LNCap), urinary bladder carcinoma (HT1376) andfibroblasts (HFF1) at distinct times: 15, 30, 60, 90 and 120 seconds (s). Results areexpressed as percentage of metabolic activity normalized to control.P C 3T im e  ( s )Protein Content (%)1530609012005 01 0 0*********L nC apT im e  ( s )Protein Content (%)1530609012005 01 0 0*********H T 1376T im e  ( s )Protein Content (%)1530609012005 01 0 0***************T im e  ( s )Protein Content (%)1530609012005 01 0 0******H FF 1Figure 2 - SRB assay results 24 h after plasma therapy application in different human celllines: prostate adenocarcinoma (PC3 andLNCap), urinary bladder carcinoma (HT1376) andfibroblasts (HFF1) at distinct times: 15, 30, 60, 90 and 120 seconds (s). Results areexpressed as percentage of protein content normalized to control.

http://rihuc.huc.min-saude.pt/bitstream/10400.4/2111/1/Plasma%20p%c3%b3ster.pdf

Selective ablating urologic cancers with cold atmospheric plasma

Abstract

Similar works

Full text

Available Versions

Name not available

Repositório Institucional dos Hospitais da Universidade de Coimbra